BioSpace News Archive

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences:.

First quarter GAAP net sales of $1.10 billion, an increase of 3% year-over-year; non-GAAP organic net sales increased 4% year-over-year

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2021 and provides a business update.

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Thursday, May 13, 2021, at 4:30 p.m. ET, to discuss its corporate and financial results for the first quarter 2021.

Horizon Therapeutics plc announced that the Company will participate in the following conference in May:

Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA), formerly Debut Diamonds Inc. (CSE:DDI), announces the successful closing of its previously announced reverse takeover (“RTO”) of Debut Diamonds Inc. (“Debut”) by Wesana Health Inc.

Select Medical Holdings Corporation announced results for its first quarter ended March 31, 2021 and the declaration of a cash dividend.

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), announced today that it will report financial results and highlights for the quarter ended March 31, 2021

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended March 31, 2021 and provided a business update.

Organogenesis Holdings Inc. announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, and Nushield® product lines will be showcased at the 2021 Symposium on Advanced Wound Care Spring | Wound Healing Society Virtual Experience, held May 10-14.